Lipoprotein(a), written Lp(a), is an LDL-like particle carrying an additional protein that makes it independently atherogenic. It is roughly 70 to 90 percent genetically determined, which makes it the clearest exception to the premise that tracked markers respond to effort. Knowing your number still matters, because it changes how aggressively the markers you can move should be managed.
- Roughly 90 percent genetically determined, and largely fixed across your adult life.
- Below 75 nmol/L is the National Lipid Association low-risk threshold.
- Deliberately excluded from Longevity Coach IQ projections, because a projection would imply a lever that doesn’t exist.
- A once-in-a-lifetime test for most people. Repeating it annually tells you nothing new.
What Lp(a) is, and why it is different
An Lp(a) particle is essentially an LDL particle with an extra protein, apolipoprotein(a), attached. That addition does two things. It makes the particle atherogenic in the same way LDL is, contributing to plaque formation. And because apolipoprotein(a) structurally resembles plasminogen, a protein involved in breaking down clots, it may also interfere with clot clearance.
So it carries a dual mechanism, and it is independently associated with cardiovascular disease and with aortic stenosis after adjusting for other lipids. A standard lipid panel doesn’t measure it. You have to ask for it specifically, and most people never do.
Why lifestyle barely moves Lp(a)
Lp(a) concentration is determined largely by variation at the LPA gene, with heritability estimates consistently around 70 to 90 percent. Your level is set early, remains broadly stable through adult life, and doesn’t meaningfully respond to the things that move other lipids.
This is worth sitting with, because it runs against how the rest of this encyclopedia works. Diet and exercise change triglycerides within weeks and ApoB within months. Applied to Lp(a), the same interventions produce close to nothing.
Statins, which lower LDL substantially, don’t lower Lp(a) and may raise it slightly. Niacin lowers it modestly, without evidence that doing so improves outcomes. That gap between moving a number and improving an outcome is the recurring theme of this marker.
What counts as an elevated Lp(a)
| Tier | Level (nmol/L) | Basis |
|---|---|---|
| Low risk | Below 75 nmol/L (30 mg/dL) | National Lipid Association, 2024 |
| Intermediate risk | 75–125 nmol/L (30–50 mg/dL) | National Lipid Association, 2024 |
| High risk | 125 nmol/L (50 mg/dL) and above | National Lipid Association, 2024 |
| Top 5% | Below 30 | App interpolation |
| Top 1% | Below 10 | App interpolation |
Only the first three rows are guideline thresholds. The tighter bands below it are Longevity Coach IQ's own interpolation, included so the marker sits on the same percentile scale as everything else, and flagged here so you know which numbers carry guideline weight and which don’t.
Lp(a) represents a continuum of risk rather than a threshold at a dichotomous cut-point. The 2024 National Lipid Association update explicitly calls for retiring the idea of a single dichotomous threshold, and states that clinical decision-making should be influenced by the degree of elevation together with a person’s other risk factors rather than by the mere presence of elevated Lp(a).
An intermediate result is therefore not a reassurance, and a high result is not a verdict. The risk categories apply across races and ethnicities.
roughly one in five people is at or above 125 nmol/L. Units also vary between laboratories, and nmol/L and mg/dL don’t convert with a single reliable factor, so compare like with like.
Lp(a) interpreter
Enter your result against the National Lipid Association cut-off. Check your units first, since some labs report mg/dL instead of nmol/L.
Why Lp(a) is excluded from projections
Longevity Coach IQ projects where markers will be if you stay consistent. Lp(a) is deliberately left out of that system, and the app says so directly on My Plan rather than quietly omitting it:
“Not projected: Lp(a), Cystatin C, TSH, and Free T3 are excluded here. Lp(a) is ~90% genetically determined, and there isn’t credible evidence the others respond meaningfully to habits and training within a realistic timeframe. They’re still tracked normally in Your Lab.”
The reasoning is straightforward. A projection implies a lever. Showing a hopeful downward line for a marker that is 90 percent genetic would be inventing one, and the marker would then quietly undermine trust in every projection that is real.
It is still tracked and still scored. It is simply not pretended to be trainable.
What to do if your Lp(a) is high
The standard guidance is to discuss it with a healthcare provider, because the useful responses are medical rather than behavioral. That said, an elevated result does change what your other numbers are worth.
From the EPIC-Norfolk study, reported in the 2022 European Atherosclerosis Society consensus statement, among people with Lp(a) above 50 mg/dL, those with few traditional risk factors had a one-third to two-thirds lower risk of an atherosclerotic cardiovascular event over 11.5 years of follow-up than those with an unhealthy lifestyle.
Same unchangeable genetic burden, substantially different outcomes depending on the modifiable factors.
The same statement makes the point in both directions. A person with high Lp(a) but none of the traditional risk factors may never develop atherosclerotic cardiovascular disease, whereas in someone with several traditional risk factors, overall risk rises even within the 75 to 125 nmol/L intermediate band.
Cardiovascular risk is multiplicative rather than additive. If Lp(a) has raised your baseline and you can’t lower it, the value of controlling everything else rises: ApoB, blood pressure, smoking status, glycemic control. A high Lp(a) is a reason to be more rigorous with the modifiable factors, not a reason to conclude the outcome is settled.
It is also heritable, which makes it family information as much as personal information.
When to test Lp(a)
Once is usually enough. Levels are stable across adult life, so unlike triglycerides or HbA1c, repeat testing doesn’t track a trajectory, it re-measures a constant.
The case for testing at all is strongest with a family history of early cardiovascular disease, an event that seems unexplained by conventional risk factors, or simply wanting a complete picture before deciding how aggressively to manage the rest.
Why almost nobody has this test
Roughly one in five people have elevated Lp(a), yet measurement rates are very low. A study of Lp(a) testing across 11 US health systems between 2015 and 2019 found Lp(a) was measured in only 0.06 percent of patients per year.
Two guideline bodies say it should be. The 2024 National Lipid Association focused update recommends Lp(a) be measured at least once in every adult. The 2019 ESC/EAS dyslipidaemia guideline makes the same recommendation, that Lp(a) assessment should be considered at least once in a lifetime to identify very high inherited levels.
What an Lp(a) result tells you about your starting position
Lp(a) sits in the Systemic Health domain, available in the Complete tracking mode, and it is scored like any other marker while being excluded from projections.
Its practical role is as context rather than as a target. It tells you what starting position you are working from, which is genuinely useful even though, uniquely among the markers here, it isn’t something you can change.
Sources
Key references for the claims on this page. Where a figure is attributed to a specific study or body, it is named here.
- National Lipid Association, 2024 scientific statement: below 75 nmol/L is the low-risk cut-off. The Top 5 percent and Top 1 percent sub-splits below that figure are Longevity Coach IQ interpolations, not guideline thresholds.
- Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal, 2022. DOI
- Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. Journal of Clinical Lipidology, 2024. The three risk bands used above and the recommendation to measure Lp(a) at least once in every adult.
Frequently asked
What is a normal Lp(a) level?
Below 75 nmol/L is the National Lipid Association low-risk threshold, and 125 nmol/L is the high-risk threshold. Roughly one in five people worldwide sits at or above 125 nmol/L. Units vary between labs, with some reporting mg/dL instead, and the two aren’t interchangeable, so check which your result uses.
Can I lower Lp(a) with diet or exercise?
Essentially no, and this is the defining feature of the marker. Lifestyle changes that meaningfully improve almost every other lipid marker have minimal effect on this one. Niacin and some hormonal treatments lower it modestly without demonstrated outcome benefit.
If I can’t change it, why measure it?
Because it changes what you do about everything else. An elevated Lp(a) raises baseline cardiovascular risk, which makes aggressive management of the factors you can control, ApoB, blood pressure, smoking status, more valuable rather than less. It also flags a heritable risk worth telling family about.
How often should I test it?
Once, for most people. Levels are largely stable across adult life, so an annual test spends money to re-learn something you already know. Retest only if a clinician has a specific reason.
Is Lp(a) the same as LDL?
No. The particle is LDL-like but carries apolipoprotein(a), an additional protein that makes it both atherogenic and prothrombotic. A standard lipid panel doesn’t measure it, so a normal LDL result tells you nothing about your Lp(a).
Should my children be tested?
The 2024 National Lipid Association statement recommends cascade screening of first-degree relatives of patients with elevated Lp(a). It is heritable, so an elevated result in a parent is relevant to children. Whether and when to test them is a conversation with a doctor rather than a general recommendation, and the answer depends on family history.
Are there drugs that lower it?
Targeted therapies are in late-stage trials and look pharmacologically effective at lowering the number. Whether lowering it reduces cardiovascular events hasn’t yet been shown, which is the outcome that matters and the reason none is approved for that purpose.
Does a high Lp(a) mean I will have a heart attack?
No. It raises risk; it doesn’t determine outcome. Plenty of people with elevated Lp(a) and well-controlled ApoB, blood pressure and lifestyle never have an event. The number is one input, not a verdict.